Genflow Biosciences PLC's Eric Leire joins Proactive London to talk about their research and development on gene therapies designed to target the ageing process and to reduce and delay the incidence of age-related diseases.
This will be done through novel therapeutics targeting ageing in humans by using genetically modified adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant that is found in centenarians.
SIRT6 has already been shown to have improved capabilities to repair DNA damage. This will improve health spans (living healthier for longer) and potentially, life expectancy.